Investor · 1 deal
Every published round Eli Lilly and Company took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| AdvanCell | Series D+ | 15 Jul 2026 | $450m | Participant | Startup Daily, Cut Through Venture, Forbes Australia (Mon 12 Oct 2026), Forbes Australia (Thu 3 Sep 2026), Forbes Australia (Thu 16 Jul 2026), Brandon Capital, advancell.com.au, Brandon Capital portfolio, Brandon Capital portfolio, Tenmile portfolio |
Companies Eli Lilly and Company has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| AdvanCell | 15 Jul 2026, Series D+ | 1 | 0 |
Fund closes reported for Eli Lilly and Company, as distinct from the investments it has made.
Companies Eli Lilly and Company has backed that another company then bought. An exit for the holding, not a deal Eli Lilly and Company did.
Stories naming Eli Lilly and Company. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Amplia has locked in the design of its PRROSE phase two study pairing narmafotinib with chemotherapy in ovarian cancer, to run with ANZGOG across Australia and New Zealand, recruiting about 26 patients.
Biotech Amplia Therapeutics has completed planning for its PRROSE phase two trial pairing narmafotinib with chemotherapy in ovarian cancer, working with ANZGOG, with patient recruitment targeted before the end of 2026.
Brisbane radiopharmaceutical developer AdvanCell has closed an oversubscribed Series D round, led by Ally Bridge Group and Alpha Wave with several institutional investors returning, to fund late-stage prostate cancer trials and US manufacturing.